| Literature DB >> 30543696 |
Lucas Moreira Dos Santos1, Carolina Georg Magalhães1, Paula de Lima Telmo1, Michele Pepe Cerqueira1, Rafael Amaral Donassolo1, Fábio Pereira Leivas Leite1, Guita Rubinsky Elefant2, Luciana Farias da Costa Avila3, Carlos James Scaini3, Ângela Nunes Moreira1, Fabricio Rochedo Conceição1.
Abstract
Toxocariasis is a neglected zoonosis that affects children and adults. Recombinant proteins have been widely investigated for diagnosis, achieving high sensitivity and specificity in an overall population; however, little is known about age as a factor in its application. This study aims to investigate the diagnostic potential of Toxocara canis TES-30 and TES-120 recombinant proteins in humans, differentiating between its performance in children and adults. Serum samples collected from children and adults seropositive to Toxocara spp. were tested with indirect ELISA using T. canis TES-30 and TES-120 recombinant proteins produced in Escherichia coli. While rTES-30 sensitivity was not affected by age (81.8% in children and 87% in adults), rTES-120 sensitivity severely decreased in children to only 63.6%, down from 95.7% in adults. Furthermore, the sensitivity of rTES-30 increased to 97.8% after Western blotting confirmation. High specificity (>94%) against other geohelminths was reported for both recombinant proteins. Our study favors the use of rTES-30 with total IgG as the primary antibody in an indirect ELISA assay as a tool for epidemiological human studies.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30543696 PMCID: PMC6292589 DOI: 10.1371/journal.pone.0208991
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Agarose gel stained with ethidium bromide presenting PCR products.
Lane 1: PCR Negative Control (PCR Mix). Lane 2: pAE rTES-30 Clone 1. Lane 3: pAE rTES-120 Clone 1. Lane 4: pAE rTES-30 Clone 2. Lanes 5: pAE rTES-120 Clone 2. Lanes 6: Ladder 100 pb (Ludwig Biotecnologia, Brazil).
Primer details of rTES-30 and rTES-120 for confirmation of cloning in expression vector pAE.
| Protein | Forward Primer Sequence | Reverse Primer Sequence | Size of Product |
|---|---|---|---|
| rTES-30 | 641 | ||
| rTES-120 | 502 |
Optimum sensibility and specificity for each protein and antibody after receiver operating characteristic (ROC) analysis.
| Protein/Antibody | Positive Samples (Sensitivity) | Negative Samples (Specificity) |
|---|---|---|
| rTES-30/IgG | 38/45 (84.4%) | 45/45 (100%) |
| rTES-30/IgG2 | 4/45 (8.9%) | 40/45 (88.9%) |
| rTES-30/IgG4 | 10/45 (22.2%) | 44/45 (97.8%) |
| rTES-120/IgG | 34/45 (75.6%) | 45/45 (100%) |
| rTES-120/IgG2 | 6/45 (13.3%) | 43/45 (95.6%) |
| rTES-120/IgG4 | 23/45 (51.1%) | 44/45 (97.8%) |
Specificity of recombinant proteins against a variety of common geohelminths.
| Cross-Reactivity | ||||||
|---|---|---|---|---|---|---|
| Ancylostomids | ||||||
| rTES-30 | 0/9 | 0/2 | 0/4 | 1/16 | 1/6 | 0/3 |
| rTES-120 | 2/9 | 0/2 | 0/4 | 0/16 | 1/6 | 0/3 |
a) Cut-off for each antigen was calculated by ROC curve assay of 40 Toxocara spp. negative patients.
Sensitivity and specificity for each protein and antibody after ROC analysis, separated by adult and child samples.
| Protein/Antibody | Adult Positive Samples (Sensitivity) | Adult Negative Samples (Specificity) | Children Positive Samples (Sensitivity) | Children Negative Samples (Specificity) |
|---|---|---|---|---|
| rTES-30/IgG | 20/23 (87%) | 19/19 (100%) | 18/22 (81.8%) | 26/26 (100%) |
| rTES-30/IgG2 | 1/23 (4.3%) | 18/19 (94.7%) | 1/22 (4.5%) | 25/26 (96.2%) |
| rTES-30/IgG4 | 6/23 (26.1%) | 19/19 (100%) | 1/22 (4.5%) | 26/26 (100%) |
| rTES-120/IgG | 22/23 (95.7%) | 19/19 (100%) | 14/22 (63.6%) | 26/26 (100%) |
| rTES-120/IgG2 | 2/23 (8.7%) | 18/19 (94.7%) | 4/22 (18.2%) | 25/26 (96.2%) |
| rTES-120/IgG4 | 16/23 (69.6%) | 19/19 (100%) | 6/22 (27.3%) | 26/26 (100%) |
Fig 2(A) Western blot analysis of rTES-30 antigen probed with serum that was close to the ELISA cut-off. Lane 1: PageRuler Prestained Protein Ladder (Thermo Fischer Scientific, USA). Lane 2: positive/loading control. Lane 3: negative control. Lanes 4–7: sera from four different Toxocara-seropositive patients. (B) Western blot analysis of rTES-30 antigen probed with serum that was close to the ELISA cut-off. Lane 1: PageRuler Prestained Protein Ladder (Thermo Fischer Scientific, USA). Lane 2: positive/loading control. Lane 3: negative control. Lanes 4–7: sera from apparently healthy people.